BioPharm International - May 2022

BioPharm International- May 2022

Issue link: https://www.e-digitaleditions.com/i/1467950

Contents of this Issue

Navigation

Page 22 of 35

www.biopharminternational.com May 2022 eBook BioPharm International 23 PARTING THOUGHTS As parting thoughts, Mahler expresses his belief that "outsourcing and the development and commercialization of medicines in genera l should be more a 'system thinking' approach. Companies or outsourcing services may be getting so specific about one given part of the product, that the inter- connectivit y and dependency of all the components of a drug product are being forgotten: a sterile product can only be reliably and reproducibly man- ufactured if the formulation, primary packaging, and processing parameters are wisely chosen in its entity." Furthermore, Mahler stresses the importance of focusing on 'people'— patients and employees—as well as the planet. "We, at ten23 health, hence embed considerations of fairness and sustainability in all we do. There is only one Planet," he adds. Pretorius also points to the larger operating system, observing that out- sourcing can also prove beneficial in t he a rea of reg u lator y operat ions through a id ing w ith submissions, product registration, tracking agency interactions, and so on. "This [ser- vice] requires working in tandem with partner internal regulatory teams and carefully defining roles and responsi- bilities to assure alignment," he says. "At Parexel, our regulatory outsourc- ing teams consist of former regula- tors from FDA, European Medicines Agency, National Medical Products Administration, among others with specialized knowledge and first-hand experiences of regulatory expectations." While there is much to weigh and evaluate, the uptick in outsourcing appears well founded on benefits and advantages. This has led to what might be termed a 'run' on available sched- uled slots within CMOs and CDMOs. Currently, not only must one place a large cash down payment but also the requesting company must now face wait times of around 12 months to get their place in the que. However, in this case good things take time, and time taken pays dividends at the (pun intended) finish line. REFERENCE 1. PWC, Current Trends and Strategic Options in the Pharma CDMO Market, PriceWatershoueCoopers, November 2019. BP Partnerships for Outsourcing Development powered by A 24-hour streaming program For Health Care Professionals, By Health Care Professionals Season 6 is streaming now! www.medicalworldnews.com While there is much to weigh and evaluate, the uptick in outsourcing appears well founded on benefits and advantages.

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - May 2022 - BioPharm International- May 2022